Exagen Inc (XGN)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $96.19M
Last updated: Nov 17, 2026 at 4:13 PM ET
Exagen Inc (XGN) Statistics
Exagen (XGN) has a market cap of $96.19M and an enterprise value of $90.91M. Its share count is up 8.32% from a year earlier. It kept -25.14% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 5.49% below the market cap, as cash exceeds debt.
| Market Cap | $96.19M |
|---|---|
| Enterprise Value | $90.91M |
| Latest price (Nov 17, 2026) | $3.76 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.3x and 6.8x. Its year-end P/S ranged from 0.7x to 4.0x from 2020 to 2025.
| P/S Ratio | 1.3x |
|---|---|
| Forward P/S | 1.3x |
| P/B Ratio | 6.8x |
Price Statistics
The stock is down 58.27% over 52 weeks and trades 50.26% below its 50-day average.
| Beta (1Y) | 2.67 |
|---|---|
| 52-Week Change | -58.27% |
| 1-Month Change | -49.39% |
| 3-Month Change | -49.39% |
| 6-Month Change | +0.80% |
| 5-Year Change | -26.08% |
| Total Return (1Y) | -58.27% |
| Total Return (3Y CAGR) | +33.73% |
| Total Return (5Y CAGR) | -21.05% |
| Return vs SPY (1Y) | -65.76% |
| Max Drawdown (1Y) | -68.71% |
| Max Drawdown (3Y) | -77.84% |
| Sharpe Ratio (1Y) | -0.85 |
| Correlation with SPY (1Y) | 0.40 |
| 50-Day Average | $7.56 |
| 200-Day Average | $5.12 |
| 52-Week Range | $2.59 to $9.22 |
| RSI (14 Days) | 27.3 |
| Average Volume (20 Days) | 781.74K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.46x current liabilities, and total debt is 1.66x shareholder equity.
| Current Ratio | 3.46x |
|---|---|
| Quick Ratio | 3.46x |
| Debt / Equity | 1.66x |
| Interest Coverage | -2.95x |
Returns and Efficiency
Return on invested capital is -40.37% over the last 12 months, against a 5-year average of -44.80%.
| Return on Equity (ROE) | -131.92% |
|---|---|
| Return on Assets (ROA) | -32.83% |
| Return on Invested Capital (ROIC) | -40.37% |
| Return on Capital Employed (ROCE) | -34.96% |
| ROA (5Y Average) | -37.30% |
| ROIC (5Y Average) | -44.80% |
| Asset Turnover | 1.22x |
| Receivables Turnover | 6.05x |
Scores
XGN has an Altman Z-Score of -5.82, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -5.82 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $72.30M over the last 12 months is up 13.67% from the 12 months before.
| Revenue | $72.30M |
|---|---|
| Revenue Growth (YoY) | +13.67% |
| Gross Profit | $42.46M |
| Operating Income | -$14.52M |
| Pretax Income | -$18.12M |
| Net Income | -$18.17M |
| EBITDA | -$10.45M |
| EBIT | -$14.77M |
| Reported EPS (TTM) | -$0.85 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 24.90% of the $55.35M in total assets.
| Cash and Equivalents | $28.09M |
|---|---|
| Total Debt | $22.81M |
| Net Cash | $5.28M |
| Net Cash Per Share | $0.21 |
| Working Capital | $32.23M |
| Shareholder Equity | $13.78M |
| Book Value Per Share | $0.55 |
| Total Assets | $55.35M |
| Total Liabilities | $41.58M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.01M of capital spending, operating cash flow left -$13.03M of free cash flow.
| Operating Cash Flow | -$12.02M |
|---|---|
| Capital Expenditures | $1.01M |
| Free Cash Flow | -$13.03M |
| FCF Per Share | -$0.54 |
| Depreciation and Amortization | $4.32M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -20.08%, against a 5-year average of -48.00%.
| Gross Margin | 58.74% |
|---|---|
| Operating Margin | -20.08% |
| Pretax Margin | -25.07% |
| Net Margin | -25.14% |
| EBITDA Margin | -14.45% |
| EBIT Margin | -20.43% |
| FCF Margin | -18.02% |
| Gross Margin (5Y Average) | 55.61% |
| Operating Margin (5Y Average) | -48.00% |
| Net Margin (5Y Average) | -52.36% |
Growth
Revenue grew 13.47% a year over 3 years.
| Revenue Growth (3Y CAGR) | +13.47% |
|---|---|
| Revenue Growth (5Y CAGR) | +9.66% |
| Book Value Per Share Growth (2Y CAGR) | -20.24% |
| Tangible Book Per Share Growth (2Y CAGR) | -20.24% |
Dividends and Yields
XGN does not pay a dividend. Its free cash flow yield is -13.94%.
| FCF Yield | -13.94% |
|---|---|
| Buyback Yield | -7.40% |
| Shareholder Yield | -7.40% |
Peer Position
Against 10 similar companies, XGN has the 9th highest P/S and the 9th highest ROIC.
P/S RatioPeer median 4.5x
ROICPeer median 5.79%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +11.87%
| P/S Ratio | 1.3x vs 4.5x median |
|---|---|
| ROIC | -40.37% vs 5.79% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +13.67% vs +11.87% median |
Analyst Forecast
Consensus estimates put revenue growth at 9.72% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +9.72% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About XGN
What is XGN's market cap?
Exagen has a market cap of $96.19M. Its enterprise value, which adds debt and subtracts cash, is $90.91M.
How many shares of XGN are outstanding?
Exagen has 24.85M shares outstanding. The count is up 8.32% from a year earlier.
Does XGN pay a dividend?
No. Exagen does not pay a dividend.
How much debt does XGN have?
Exagen has $22.81M of total debt and $28.09M of cash and equivalents, a net cash position of $5.28M.
XGN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors